INPPL1 and kidney disorder: The other research line to pursue is the identification of SHIP2 inhibitors more potent than metformin, especially in terms of better inhibition of SHIP2 in podocytes, followed by defining whether these molecules provide better renoprotection than metformin in diabetic animal models with kidney disease.